Percheron Therapeutics Limited (OTC: ATHJY)
|
|
---|---|
Pricing data not available |
Open: | $ n/a | Volume: | n/a | |
---|---|---|---|---|
High: | $ n/a | Yield(%) | n/a | |
Low: | $ n/a | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | n/a | |
EPS ($) | n/a | Shares Out: | n/a |
% Price Change (last 4 weeks): | -9.89 |
---|---|
% Price Change (last 13 weeks): | -2.56 |
% Price Change (last 26 weeks): | 29.06 |
% Price Change (last 52 weeks): | 35.11 |
% Price Change (year to date): | 32.92 |
Return on Equity (%): | -72.29 |
---|---|
Return on Assets (%): | -63.85 |
Return on Invested Capital (%): | -107.31 |
Gross Profit Margin (%): | n/a |
---|---|
Net Profit Margin (%): | n/a |
Operating Profit Margin (%): | 0.00 |
|
|
50-day Moving Average: | $n/a |
---|---|
200-day Moving Average: | $n/a |
Avg. Daily Vol. (last 50 days): | n/a |
Avg. Daily Vol. (last 200 days): | n/a |
52-wk high: | $n/a |
52-wk low: | $n/a |
Bid: | $n/a |
Ask: | $n/a |
Percheron Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. It operates through the ATL1102, and ATL1103 segments. The ATL1102 segment represents the second generation antisense inhibitor of CD49d, the alpha subunit of very late antigen-four. The ATL1103 segment refers to atesidorsen is an antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin. The company was founded on November 13, 2000 and is headquartered in Toorak, Australia.
|
Percheron Therapeutics Limited
Collins Place 35 Collins Street Level 30 Melbourne VI 3000 Phone: 61.3.9827.8999 Fax: 61.3.9829.7701 http://www.PercheronTx.com |
Earnings (1year) ($): | -0.21 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | 0.20 |
Cash Flow ($): | -0.23 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | n/a |
Price/Book (x): | 3.96 |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 4.51 |
---|---|
Current Ratio (x): | 4.51 |
LT Debt/Equity (x): | 0.48 |
Total Debt/Equity (x): | 1.42 |